TRIDOS · Targeted Radiotherapy Internal Dosimetry: A platform for individualized patient dosimetry and radiobiological assessment
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-05-01 → 2021-10-30
- EU contribution
- €172,932
- Participants
- 1
- Scheme
- MSCA-IF-EF-RI
Lines connect the coordinator with its partners.
Results in brief
Targeted Radiotherapy Internal Dosimetry: A platform for individualized patient dosimetry and radiobiological assessment
Targeted radionuclide therapy (TRNT) is a growing type of radiotherapy in which radioactive compounds with high tumor affinity are administered to patients. Several limitations jeopardize the design of optimal treatments in this promising therapy. On one hand, the dose delivered to the patient depends on the anatomy of the patient and the biodistribution of the administered drug, which is greatly heterogeneous among individuals. Due to this complexity, internal dosimetry is far from the accuracy achieved in External radiotherapy (ERT). In addition, the biological effects of TRNT differ from those observed in ERT, due to the long-lived radionuclides employed. The reliable radiobiological models used to quantify ERT effectiveness and toxicity are therefore not directly extensible to TRNT. As a result, TRNT treatments are currently primarily based on the administration of empirical activities to patients. This limits the potential of TRNT, particularly in terms of therapy individualization. The action “Targeted Radiotherapy Internal Dosimetry: A platform for individualized patient dosimetry and radiobiological assessment” aimed to develop methods for the personalization of TRNT. Cancer is the second leading cause of death worldwide, and its social and economic impact increases every year. Despite the major scientific and clinical advances in cancer treatment in the last decades, cancer remains a global complex health concern with limited therapies. Radiotherapy is one of the main clinical strategies used to treat cancer, being applied to approximately 50% of all cancer patients. By working on the development of personalized dosimetry and radiobiological modelling of TRNT, the products of this Marie Skłodowska-Curie Action (MSCA) provided promising tools for the devolpemnt of better cancer treatments, with direct impact on both the scientific community and the society. The objectives of this project have been to develop methodologies for (a) accurate, individualized dosimetry, and (b) radiobiological assessment of TRNT, shifting from the current paradigm of empirical treatment to the era of personalized treatment. In addition, this MSCA Individual Fellowship aimed to consolidate my professional career as independent researcher.
Data: CORDIS, © European Union
Project objective
In radiation therapy (RT), which is used in more than 50% of cancer treatments, the dose delivered to the tumour/normal tissue determines tumour control and toxicity. Targeted radionuclide therapy (TRNT) is an effective growing type of RT in which radiative compounds with high tumour affinity are administered to patients. While in external RT there are well-defined methodologies to accurately determine the dose, this is not the case in TRNT. Traditionally, TRNT dosimetry is obtained from simple biokinetic models, developed many years ago, and non-individualized dosimetric factors calculated in phantoms. This dosimetry is inaccurate and not patient individualized. The recent European council directive 2013/59/Euratom, transposed on Feb 2018, has clearly highlighted the need to accurately report all doses from radiopharmaceutical procedures, hardening the criteria of previous regulations. The objective of this project is to develop methodologies for the accurate, individualized dosimetry and radiobiological assessment of TRNT, shifting from the current paradigm of empirical treatment to the era of personalized treatment. This will be achieved by the following actions: a) adaptation of Monte Carlo codes for patient’s internal dose calculation, considering novel biokinetic models of the drug biodistribution; b) development and implementation of radiobiological algorithms to evaluate tumour control/toxicity; and c) implementation of a platform useful for the clinical practice, incorporating these models and allowing easy handling and user interactivity. To successfully address this, the researcher experience will be combined with the host organisation (FIDIS) capabilities, a leading biomedical research institute where the supervisor is already involved in TRNT research. FIDIS will also provide clinical data for the models development/validation, an interdisciplinary environment and a training program greatly contributing to re-enforce the researcher professional maturity
Original text from CORDIS.
Participants
- FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA · Santiago De CompostelaCoordinatorSpain
Links
Data: CORDIS, © European Union